Strongbridge Biopharma plc

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genentech/Pieris Pact Follows Abandoned

Patients suffering from Cushing’s syndrome, which caused by high levels of cortisol that are often the result of a benign tumor of the pituitary gland, could soon have a new treatment option now that

The first weeks of March brought in a flurry of new drug applications to the US Food and Drug Administration, including two new molecular entities from big pharma stalwart Merck & Co., Inc. . Towards

With 52 initial public offerings by biopharmaceutical companies in the US the 2020 total has surpassed 2019’s 50 drug developer IPOs after Metacrine, Inc. , Dyne Therapeutics , Athira Pharma, Inc.